The challenges that adolescents and young adults face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
The challenges that adolescents and young adults (AYAs) face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, who presented findings on the different outcomes between children and AYAs with acute lymphoblastic leukemia (ALL) at the 59th American Society of Hematology Annual Meeting.
Transcript
How does social support play a role in outcomes among adolescents and young adults with ALL?
It’s not something that we looked at specifically in terms of social support but I think that it really is important when we look at the fact we saw that the duration of treatment, the length of maintenance treatment is really important. We know that these patients are in a really volatile time in their lives. Everyone comes in with a lot of important things happening in their life and that has been disrupted and so others have shown how important social support is and we’ve shown the importance of the duration of treatment. So together I think that just means that making sure we are paying attention to the social needs of these patients is crucial.
What are the unique challenges facing AYAs after treatment?
There are so many challenges that these patients face that are unique and I think that people are really working hard to try to figure out what we can do to help them. But I think the minute they walk into the door, thinking of them as a unique group of patients is the first thing we can do and just recognizing that their lives have been disrupted in a way that younger patients and older patients don’t experience and trying to understand that unique patient’s needs.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More